Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
Sell
26
PHAR Quote, Financials, Valuation and Earnings
Last price:
$7.90
Seasonality move
:
-14.93%
Day range:
$8.02 - $8.16
52-week range:
$6.65 - $11.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.21x
P/B ratio:
2.52x
Volume:
1.1K
Avg. volume:
6.5K
1-year change:
-24.3%
Market cap:
$558.1M
Revenue:
$297.2M
EPS (TTM):
-$0.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHAR
Pharming Group
|
$64.1M | -$0.03 | 15.36% | -86.84% | $30.00 |
|
ARGX
argenx SE
|
$829.9M | $2.22 | 88.23% | 536.98% | $778.12 |
|
MRUS
Merus NV
|
$7.5M | -$1.05 | 2.89% | -74.43% | $86.79 |
|
PHVS
Pharvaris NV
|
-- | -$0.95 | -- | -55.88% | $35.67 |
|
PRQR
ProQR Therapeutics NV
|
$4.9M | -$0.16 | 1.34% | -63.67% | $10.67 |
|
QURE
uniQure NV
|
$6.9M | -$1.08 | -27.53% | -27.05% | $37.26 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHAR
Pharming Group
|
$8.16 | $30.00 | $558.1M | -- | $0.00 | 0% | 2.21x |
|
ARGX
argenx SE
|
$605.38 | $778.12 | $37B | 47.63x | $0.00 | 0% | 17.36x |
|
MRUS
Merus NV
|
$43.22 | $86.79 | $3B | -- | $0.00 | 0% | 76.80x |
|
PHVS
Pharvaris NV
|
$13.94 | $35.67 | $759.6M | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$1.19 | $10.67 | $125.2M | -- | $0.00 | 0% | 5.01x |
|
QURE
uniQure NV
|
$9.65 | $37.26 | $521.8M | -- | $0.00 | 0% | 17.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHAR
Pharming Group
|
27.08% | -1.600 | 12.07% | 3.02x |
|
ARGX
argenx SE
|
-- | 1.058 | -- | 6.40x |
|
MRUS
Merus NV
|
-- | 0.674 | -- | 6.22x |
|
PHVS
Pharvaris NV
|
-- | -1.337 | -- | -- |
|
PRQR
ProQR Therapeutics NV
|
4.92% | 1.701 | 1.71% | 3.89x |
|
QURE
uniQure NV
|
115.15% | -2.868 | 5.93% | 9.32x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHAR
Pharming Group
|
$80.5M | $6.6M | -3.37% | -5.03% | 9.86% | $9.2M |
|
ARGX
argenx SE
|
$665.8M | $101.6M | 18.03% | 21.33% | 11.81% | -$147M |
|
MRUS
Merus NV
|
-- | -$88.7M | -38.4% | -38.4% | -969.93% | -$66.7M |
|
PHVS
Pharvaris NV
|
-- | -$41.7M | -- | -- | -- | -$38.1M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$10.7M | -57.21% | -62.97% | -150.73% | -$9.8M |
|
QURE
uniQure NV
|
$4.6M | -$42.5M | -131.71% | -239.27% | -1101.88% | -$52.9M |
Pharming Group vs. Competitors
-
Which has Higher Returns PHAR or ARGX?
argenx SE has a net margin of 3.99% compared to Pharming Group's net margin of 15.95%. Pharming Group's return on equity of -5.03% beat argenx SE's return on equity of 21.33%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group86.82% $0.06 $304.3M ARGXargenx SE90.16% $11.87 $5.5B -
What do Analysts Say About PHAR or ARGX?
Pharming Group has a consensus price target of $30.00, signalling upside risk potential of 267.65%. On the other hand argenx SE has an analysts' consensus of $778.12 which suggests that it could grow by 28.54%. Given that Pharming Group has higher upside potential than argenx SE, analysts believe Pharming Group is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group2 0 0 ARGXargenx SE13 2 0 -
Is PHAR or ARGX More Risky?
Pharming Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison argenx SE has a beta of 0.597, suggesting its less volatile than the S&P 500 by 40.308%.
-
Which is a Better Dividend Stock PHAR or ARGX?
Pharming Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or ARGX?
Pharming Group quarterly revenues are $92.7M, which are smaller than argenx SE quarterly revenues of $738.4M. Pharming Group's net income of $3.7M is lower than argenx SE's net income of $774.2M. Notably, Pharming Group's price-to-earnings ratio is -- while argenx SE's PE ratio is 47.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group is 2.21x versus 17.36x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group2.21x -- $92.7M $3.7M ARGXargenx SE17.36x 47.63x $738.4M $774.2M
-
Which has Higher Returns PHAR or MRUS?
Merus NV has a net margin of 3.99% compared to Pharming Group's net margin of -338.33%. Pharming Group's return on equity of -5.03% beat Merus NV's return on equity of -38.4%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group86.82% $0.06 $304.3M MRUSMerus NV-- -$0.41 $647.9M -
What do Analysts Say About PHAR or MRUS?
Pharming Group has a consensus price target of $30.00, signalling upside risk potential of 267.65%. On the other hand Merus NV has an analysts' consensus of $86.79 which suggests that it could grow by 100.8%. Given that Pharming Group has higher upside potential than Merus NV, analysts believe Pharming Group is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group2 0 0 MRUSMerus NV12 0 0 -
Is PHAR or MRUS More Risky?
Pharming Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merus NV has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.463%.
-
Which is a Better Dividend Stock PHAR or MRUS?
Pharming Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or MRUS?
Pharming Group quarterly revenues are $92.7M, which are larger than Merus NV quarterly revenues of $9.1M. Pharming Group's net income of $3.7M is higher than Merus NV's net income of -$30.9M. Notably, Pharming Group's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group is 2.21x versus 76.80x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group2.21x -- $92.7M $3.7M MRUSMerus NV76.80x -- $9.1M -$30.9M
-
Which has Higher Returns PHAR or PHVS?
Pharvaris NV has a net margin of 3.99% compared to Pharming Group's net margin of --. Pharming Group's return on equity of -5.03% beat Pharvaris NV's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group86.82% $0.06 $304.3M PHVSPharvaris NV-- -$0.85 -- -
What do Analysts Say About PHAR or PHVS?
Pharming Group has a consensus price target of $30.00, signalling upside risk potential of 267.65%. On the other hand Pharvaris NV has an analysts' consensus of $35.67 which suggests that it could grow by 155.9%. Given that Pharming Group has higher upside potential than Pharvaris NV, analysts believe Pharming Group is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group2 0 0 PHVSPharvaris NV4 0 0 -
Is PHAR or PHVS More Risky?
Pharming Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHAR or PHVS?
Pharming Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or PHVS?
Pharming Group quarterly revenues are $92.7M, which are larger than Pharvaris NV quarterly revenues of --. Pharming Group's net income of $3.7M is higher than Pharvaris NV's net income of -$45.9M. Notably, Pharming Group's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group is 2.21x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group2.21x -- $92.7M $3.7M PHVSPharvaris NV-- -- -- -$45.9M
-
Which has Higher Returns PHAR or PRQR?
ProQR Therapeutics NV has a net margin of 3.99% compared to Pharming Group's net margin of -216.04%. Pharming Group's return on equity of -5.03% beat ProQR Therapeutics NV's return on equity of -62.97%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group86.82% $0.06 $304.3M PRQRProQR Therapeutics NV-- -$0.10 $96.9M -
What do Analysts Say About PHAR or PRQR?
Pharming Group has a consensus price target of $30.00, signalling upside risk potential of 267.65%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $10.67 which suggests that it could grow by 796.36%. Given that ProQR Therapeutics NV has higher upside potential than Pharming Group, analysts believe ProQR Therapeutics NV is more attractive than Pharming Group.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group2 0 0 PRQRProQR Therapeutics NV5 0 0 -
Is PHAR or PRQR More Risky?
Pharming Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.250, suggesting its less volatile than the S&P 500 by 74.979%.
-
Which is a Better Dividend Stock PHAR or PRQR?
Pharming Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or PRQR?
Pharming Group quarterly revenues are $92.7M, which are larger than ProQR Therapeutics NV quarterly revenues of $4.6M. Pharming Group's net income of $3.7M is higher than ProQR Therapeutics NV's net income of -$9.9M. Notably, Pharming Group's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group is 2.21x versus 5.01x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group2.21x -- $92.7M $3.7M PRQRProQR Therapeutics NV5.01x -- $4.6M -$9.9M
-
Which has Higher Returns PHAR or QURE?
uniQure NV has a net margin of 3.99% compared to Pharming Group's net margin of -1403.2%. Pharming Group's return on equity of -5.03% beat uniQure NV's return on equity of -239.27%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group86.82% $0.06 $304.3M QUREuniQure NV88.14% -$1.50 $44.6M -
What do Analysts Say About PHAR or QURE?
Pharming Group has a consensus price target of $30.00, signalling upside risk potential of 267.65%. On the other hand uniQure NV has an analysts' consensus of $37.26 which suggests that it could grow by 286.14%. Given that uniQure NV has higher upside potential than Pharming Group, analysts believe uniQure NV is more attractive than Pharming Group.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group2 0 0 QUREuniQure NV9 2 0 -
Is PHAR or QURE More Risky?
Pharming Group has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.107%.
-
Which is a Better Dividend Stock PHAR or QURE?
Pharming Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or QURE?
Pharming Group quarterly revenues are $92.7M, which are larger than uniQure NV quarterly revenues of $5.2M. Pharming Group's net income of $3.7M is higher than uniQure NV's net income of -$73.3M. Notably, Pharming Group's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group is 2.21x versus 17.31x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group2.21x -- $92.7M $3.7M QUREuniQure NV17.31x -- $5.2M -$73.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Will NVIDIA Stock Bounce Back?
After the wild market moves during February and March, investors…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
45
DSDVY alert for Apr 16
DSV AS [DSDVY] is down 2.69% over the past day.
Buy
76
PDEX alert for Apr 16
Pro-Dex [PDEX] is down 4.66% over the past day.
Buy
82
HAGHY alert for Apr 16
Hensoldt AG [HAGHY] is down 0.02% over the past day.
